The Neuro Suite will help tackle obstacles clinicians encounter when making decisions regarding chronic neurological care. Credit: National Cancer Institute on Unsplash.

TeraRecon, a ConcertAI company, has introduced Neuro Suite, an advanced clinical suite powered by artificial intelligence (AI).

The Neuro Suite has been designed for disease triage, and differential diagnostic insights. It will also support care activation in neurological disease states such as neuro-oncology, multiple sclerosis, and dementia.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The platform can be integrated across the entire healthcare organisation, while providing the capability to tackle the obstacles encountered by clinicians while making decisions related to chronic neurological care.

ConcertAI CEO Dr Jeff Elton said: “As an AI-assisted speciality clinical suite solution, Neuro Suite was created to enhance specialists’ ability to assess neurological diseases using various types of imaging modalities.

“ConcertAI’s TeraRecon Eureka Clinical AI offers a portfolio of solutions from the AI leaders in the neurology field, including Combinostics, Imaging Biometrics, and Cercare, creating a first-in-class capability and the only open AI architecture for Clinical AI.”

Combinostics’ algorithm offers advanced brain segmentation analysis for magnetic resonance imaging (MRI) images, to enable accurate assessment of atrophy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It generates comprehensive reports and incorporates additional features that help determine the probability of a diagnosis and distinguish between various degenerative cerebral conditions such as dementia and Alzheimer’s disease.

Imaging Biometric’s algorithm is designed to offer valuable insights regarding the oxygenation and blood flow of brain tumours, providing crucial information about active tumour regions.

This will help in the diagnosis, monitoring of progression, treatment planning, and evaluation of post-treatment outcomes.

Cercare’s perfusion technology helps understand blood flow and cerebral blood volume to help evaluate neurovascular function for insights into various cerebrovascular and neuro-oncology diseases.